Bayer AG has recently rebranded itself as a life science company, of which it is still one of the largest, with 3 divisions: Pharmaceuticals, Consumer Health, and Crop Science.
With this restructuring came a new strategic innovation unit called the Bayer Lifescience Center (BLSC), which focuses on cross-species breakthroughs using state-of-the-art technology and cutting edge research.
The core team of 17 is working on a number of exciting projects, such as genome editing, regenerative medicine, and induced pluripotent stem cells (iPSCs) to cure various cardiovascular diseases, neurological disorders and diseases of the central nervous system.
